Actively Recruiting
Multiple CAR-T Cell Therapy Targeting AML
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2026-04-24
10
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple CAR T-cell therapy which combines CAR T cells against CLL-1 with CAR T cells targeting CD123 or CD33 in patients with relapsed and refractory AML. The study also aims to learn more about the function of CAR T cells and their persistency in AML patients.
CONDITIONS
Official Title
Multiple CAR-T Cell Therapy Targeting AML
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 6 months
- Confirmed expression of CLL-1, CD123 and/or CD33 in blast AML by immuno-histochemical staining or flow cytometry
- Karnofsky performance status (KPS) score higher than 80 and life expectancy greater than 3 months
- Adequate bone marrow, liver, and kidney function including cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 times upper limit of normal, AST and ALT ≤ 3 times upper limit of normal, total bilirubin ≤ 2.0 mg/dL
- Hemoglobin (Hgb) ≥ 80 g/L
- No contraindications for cell separation
- Ability to understand and willingness to provide written informed consent
You will not qualify if you...
- Severe illness or medical condition preventing protocol management, including active uncontrolled infection
- Active bacterial, fungal, or viral infection not controlled by adequate treatment
- Known HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
- Pregnant or nursing women
- Use of systemic glucocorticoids within one week prior to trial entry
- Previous treatment with any gene therapy products
- Inability to comply with study requirements as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
L
Lung-Ji Chang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here